Table 1. Baseline characteristics of patients with stage III-IVb nasopharyngeal carcinoma.
| Unmatched | Matched | |||||
|---|---|---|---|---|---|---|
| IC+CCRT | CCRT | P-value | IC+CCRT | CCRT | P-value | |
| 148(45.5%) | 177(54.5%) | 103(50.0%) | 103(50.0%) | |||
| Age (yr), | 0.175 | 0.887 | ||||
| <45 | 73(49.3%) | 74(41.8%) | 40(38.8%) | 41(39.8%) | ||
| ≥45 | 75(50.7%) | 103(58.2%) | 63(61.2%) | 62(60.2%) | ||
| Gender | 0.351 | 1.000 | ||||
| Female | 48(32.4%) | 49(27.7%) | 28(27.2%) | 28(27.2%) | ||
| Male | 100(67.6%) | 128(72.3%) | 75(72.8%) | 75(72.8%) | ||
| T stage | 0.322 | 1.000 | ||||
| 1 | 1(0.7%) | 5(2.8%) | 0(0.0%) | 0(0.0%) | ||
| 2 | 24(16.2%) | 28(15.8%) | 19(8.8%) | 19(18.4%) | ||
| 3 | 71(48.0%) | 94(53.1%) | 53(57.1%) | 53(57.6%) | ||
| 4 | 52(35.1%) | 50(28.2%) | 31(34.1%) | 31(30.1%) | ||
| N stage | 0.001 | 1.000 | ||||
| 0 | 17(11.5%) | 8(4.5%) | 5(4.9%) | 5(4.9%) | ||
| 1 | 22(14.9%) | 42(23.7%) | 20(19.4%) | 20(19.4%) | ||
| 2 | 78(52.7%) | 110(62.1%) | 67(65.0%) | 67(65.0%) | ||
| 3 | 31(20.9%) | 17(9.6%) | 11(10.7%) | 11(10.7%) | ||
| Clinical stage | <0.001 | 0.399 | ||||
| III | 70(47.3%) | 114(64.4%) | 62(60.2%) | 64(62.1%) | ||
| IVa | 50(33.8%) | 54(30.5%) | 31(30.1%) | 34(33.0%) | ||
| IVb | 28(18.9%) | 9(5.1%) | 10(9.7%) | 5(4.9%) | ||
| WHO type | 0.650 | 0.316 | ||||
| 1 | 0(0.0%) | 1(0.6%) | 0(0%) | 0(0%) | ||
| 2 | 3(2.0%) | 4(2.3%) | 0(0%) | 1(1.0%) | ||
| 3 | 145(98.0%) | 172(97.2%) | 103(100%) | 102(99.0%) | ||
Abbreviations: IC =induction chemotherapy; CCRT= concurrent chemoradiotherapy.